Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

Abstract: The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B?-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., a glutaric acid bis N-hydroxysuccinimidyl ester or a derivative thereof; or a diamine derivative. The remaining components in the multivalent construct A-B-C-D-E-B?-F are defined as follows: A is a first peptide, B is a first branching group, C is an optional first spacer, E is an optional second spacer which may be the same as or different from said first spacer C, B? is an optional second branching group which may be the same as or different from said first branching group B, and F is a second peptide which may be the same as or different from said first peptide A.

Abstract: The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the ?7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express ?7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.

Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.

Abstract: A shape-memory polymer foam is disclosed, which is formed by kneading a shape-memory copolyester with a polymeric material having a relatively lower crystallinity in a weight ratio of 15:85 to 85:15 and then conducting a foaming process. The shape-memory copolyester is a random copolymer formed from a dicarboxylic acid mixture and a diol in excess through esterfication and polycondensation. The dicarboxylic acid mixture includes 30-99 mol % of an aromatic dicarboxylic acid and 70-1 mol % of a straight aliphatic dicarboxylic acid of C4-C10. The diol includes a straight aliphatic diol of C2-C10.

Abstract: New compounds are provided that may be used to chelute a metal. The compound comprise polyazamacrocyclic compound with at least one phosphonic group substituted on at least one of the aza groups of the polyazamacrocyclic compound. Methods for preparing the compounds are also provided. Methods for preparing a diagnostic imaging agent using the compounds and methods for diagnostic imaging are further provided. Methods for preparing a therapeutic agent using the compounds and methods for therapy are further provided.

Abstract: An apparatus is disclosed including a female and a male connector wherein the female connector has a resin first connector body to which a first set of contact pins are attached and a tubular metallic shell that ensheathes the outer surfaces of the first connector body. In front of the first tubular body, two pairs of opposing overhangs are formed projecting a certain distance from the forward surface of the first connector body, whereby one pair of overhangs is bent mid-way in a direction such that their forward edges approach each other but a certain gap is provided between them forming first and second guide latching portions. One of the other pair of opposing overhangs has an insertion opening formed in it, into which the male connector is inserted and passes through the aforementioned gap in order to affect connection while being guided by the first and second guide latching portions.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.

Abstract: The present invention provides, inter alia, peptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.

Abstract: Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B?-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., a glutaric acid bis N-hydroxysuccinimidyl ester or a derivative therof; or a diamine derivative. The remaining components in the multivalent construct A-B-C-D-E-B?-F are defined as follows: A is a first peptide, B is a first branching group, C is an optional first spacer, E is an optional second spacer which may be the same as or different from said first spacer C, B? is an optional second branching group which may be the same as or different from said first branching group B, and F is a second peptide which may be the same as or different from said first peptide A.

Abstract: The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the a7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express a7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.